Abstract
The purpose of this clinicopathological study was to evaluate the effects and efficiency of combined neoadjuvant chemotherapy related to surgical margin. 100 consecutively treated squamous cell cancer patients receiving a combined neoadjuvant therapy were selected (Bleomycin—Vincristin—Methotrexate (BVM) or BVM + Mitolactol or BVM + Cisplatin). After three courses of chemotherapy, the patients were operated on. The largest diameter of the primary tumors was compared before and after chemotherapy. In the surgical specimen, the involvement of surgical margin was assessed. The largest diameter before chemotherapy was: T2 30%; T3 55%; T4A 15%. After chemotherapy, the rest tumor was assessed in the surgical specimen as: no rest 11%; <2 cm 57%; 2–4 cm 28%; 4–6 cm 4%. The no rest and <2 cm (optimal operability) tumor was observed in T2: 94%; in T3: 73%; in the T4A: 0%. Severe side effects (Grade III–IV) were not observed. There was a significant decrease in size (P < 0.0001). Of the 100 surgical specimens, 83% had clear-, 9% close- and 8% involved margins. From T4A, there was a 40% (6 patients) involved margin. Based on the significantly better size and operability of primary T2-3, the mild side effects and the high (83%) percentage of clear surgical margins, that is better than other (without preoperative chemotherapy) results, sought the use of chemotherapy is recommended before surgery. Due to the 40% involved margin, we don’t suggest surgery in T4A.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12253-009-9208-3/MediaObjects/12253_2009_9208_Fig1_HTML.gif)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12253-009-9208-3/MediaObjects/12253_2009_9208_Fig2_HTML.gif)
Similar content being viewed by others
References
Gaudi I, Kásler M (2002) The course of cancer mortality in Hungary between 1975–2001 (English abstract). Magy Onkol 46:291–295
Zs N, Velich N, Bogdán S et al (2005) The prognostic role of clinical, morphological and molecular markers in oral squamosus cell tumors. Neoplasma 52:95–101
Taylor SG (1997) Head and neck cancer. Cancer Chemot Biol Response Mod Ann 17 Elsev Science
Gibson MK, Forastiere AA (2004) Multidisciplinary approaches in the management of advanced head and neck tumors: state of art. Curr Opin Oncol 16:220–224
Forastiere AA (2004) Is there a new role for induction chemotherapy in the treatment of head and neck cancer? J Natl Cancer Inst 96:1647–1649
Gibson MK, Forestiere AA (2006) Reassassment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol 7:565–574
Bryne M, Koppang HS, Lilleng R et al (1992) Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 166:375–381
Spiro RH, Guillamondegui O, Paulin AF et al (1999) Pattern of invasion and margin assessment in patients with oral tongue cancer. Head Neck 21:408–413
Cooper JS, Pajak TF, Forastiere AA et al (2004) Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937–1944
Loree TR, Strong EW (1990) Significance of positive margins in oral cavity squamous carcinoma. Am J Surg 160:410–414
Sutton DN, Brown JS, Rogers SN et al (2003) The prognostic implications of the surgical margin in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 32:30–34
Beitler JJ, Smith RV, Silver CE et al (1998) Close or positive margins after surgical resection for the head and neck cancer patient: the addition of brachytherapy improves local control. Int J Radial Oncol Biol Phys 40:313–317
Jacobs JR, Ahmad K, Casiano R et al (1993) Implications of positive surgical margins. Laryngoscope 103:64–68
Batsakis JG (1999) Surgical excision margins: a pathologist’s perspective. Adv Anat Pathol 6:140–148
Woolgar JA, Rogers S, West CR et al (1999) Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral Oncol 35:257–265
Licitra L, Grandi C, Guzzo M et al (2003) Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 21:327–333
Bettendorf O, Piffko J, Bankfalvi A (2004) Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 40:110–119
Beckmann GK, Hoppe F, Pfreundner L et al (2005) Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 27:36–43
van Es RJJ, van Nieuw-Amerongen N, Slootweg PJ et al (1996) Resection margin as a predictor or recurrence at the primary site for T1 and T2 oral cancers. Arch Otolaryngol Head Neck Surg 122:521–525
Perez CA, Marks J, Powers W (1977) Preoperative irradiation in head and neck cancer. Semin Oncol 4:387–397
Stevens KR, Moss WT (1975) Control of localised cancer. Combination of preoperative irradiation and surgery. JAMA 232:1158–1160
Carifi VG, Ohanion ML et al (1974) Results of high dose radiation and surgery in the treatment of advanced cancer of the head and neck. Am J Surg 128:580–582
Mohr C, Bohndorf W, Carstens J et al (1994) Preoperative radiochemotherapy and radical surgery in comparison with radical surgery alone. A prospective multicentric randomised DÖSAK study of advanced squamous cell carcinoma of the oral cavity and the oropharynx (a 3-year follow up). Int J Oral Maxillofac Surg 23:140–148
Volling P, Schroder M, Muller RP et al (1994) Induction chemotherapy in primary resectable head and neck tumors: a prospective randomized trial. Int J Oncol 4:909–914
Jakobs C, Makuch R (1999) Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the head and neck contracts program. J Clin Oncol 8:838–847
Maipang T, Maipang M, Geater A et al (1995) Combination chemotherapy as induction therapy for advanced resectable head and neck cancer. J Surg Oncol 59:80–85
Olasz L, Kwashie F, Herczegh P et al (1996) A comparative study of preoperative B-V-M-M chemotherapy and irradiation in advanced squamous cell cancer of the oral cavity. Neoplasma 43:51–56
Kovacs AF, Turowski B, Ghahremani MT et al (1999) Intraarterial chemotherapy as neoadjuvant treatment of oral cancer. J Craniomaxillofac Surg 27:302–307
AlSarraf M, Martz K, Herskovic A et al (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15:277–284
Benasso M, Lionetto R, Corvo R et al (2003) Impact of the treating institution on the survival of patients with head and neck cancer treated with concomitant alternating chemotherapy and radiation. Eur J Cancer 39:1895–1898
Hironaka S, Ohtsu A, Boku N et al (2003) Nonrandomised comparison between definitive chemoradiotherapy and radical surgery in patients with T 2–3 Nany Mo squamous cell carcinoma of the esophagus. Int J Rad Oncol Biol Phys 57:425–433
Psyrri A, Kwong M, DiStasio S et al (2004) Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol 22:3061–3069
Forastiere AA, Trotti A (1999) Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional contro and survival in oropharyngeal cancer. J Natl Cancer Inst 91:2056–2066
Basu S, Khanra M, Dash B et al (1999) The role of neoadjuvant and adjuvant chemotherapy regimens consisting of different combinations of drugs in the treatment of advanced oral cancer. Med Oncol 16:199–203
Olasz L, Szabó I, Horvath A (1988) A combined treatment for advanced oral cavity cancers. Cancer 62:1267–1274
Price LA, Hill BT (1986) Impact of primary site Stage III and IV squamous cell carcinomas of the head and neck on 7-year survival figures following initial noncisplatin-containing combination chemotherapy. Resent Results Cancer Res 103:124–134
Athanasiadis J, Taylor S, Vokes EE et al (1997) Phase II. study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center. Rec Res Cancer 79:588–594
Grégoire V, Beauduin M, Humblet Y et al (1991) A phase I–II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: report from the UCL-Oncology Group, Belgium. J Clin Oncol 9:1385–1392
Gibson MK, Li Y, Murphy B et al (2005) Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23:3562–3567
Braun OM, Neumeister B, Neuhold N et al (1989) Histological grading of therapy induced regression in squamous cell carcinomas of the oral cavity. A morphological and immunohistochemical study. Path Res Pract 185:368–372
Sulfaro S, Frustaci S, Volpe R et al (1989) A pathologic assessment of residue and stromal changes after intra-arterial chemotherapy for head and neck carcinomas. Cancer 64:994–1001
Suba Z, Szabó G, Barabás J et al (1992) Histological evaluation of chemotherapeutically induced regression. Reg Cancer Treat 4:313–319
Olasz L, Németh Á, Nyárády Z et al (2004) Results and failures with or without cisplatin containing induction chemotherapy in the treatment of squamous cell carcinoma of the head and neck. Cancer Det Prev 28:65–71
Giralt JL, Gonzalez J, del Campo JM et al (2000) Preoperative induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx. Cancer 89:939–945
Posner MR, Glisson B, Frenette G et al (2001) Multicenter phase I–II trial of docetaxel, cisplatin and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19:1096–1104
Woolgar JA, Rogers SN, Lowe D et al (2003) Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncol 39:130–137
Conflict of interest and funding source
All authors state that there are no financial interests or commercial associations that may create a conflict of interest with information presented in this manuscript.
There is no involvement of any study sponsors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Olasz, L., Szalma, J., Orsi, E. et al. Neoadjuvant Chemotherapy: Does It Have Benefits for the Surgeon in the Treatment of Advanced Squamous Cell Cancer of the Oral Cavity?. Pathol. Oncol. Res. 16, 207–212 (2010). https://doi.org/10.1007/s12253-009-9208-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-009-9208-3